生命科学资讯

JPM26: US biotech’s ‘Sputnik moment,’ Pfizer’s obesity ambitions and Bristol Myers’ big year

At FDA's request, Pfizer helps ease shortage of potential autism drug

Madrigal pays $50M for Pfizer MASH drug with eye on Rezdiffra combo potential

French biotech Enodia gets €20.7M aided by Pfizer for protein degrader work

Updated: Pfizer discloses patient death in Hympavzi hemophilia trial

Novo files for CagriSema approval; Merck and Pfizer’s trial win

Chutes & Ladders—Pfizer RNA leader runs to Replicate

Pfizer bets big on obesity to offset major patent cliff

FDA ‘proactively’ hands J&J a voucher; Pfizer issues 2026 forecasts

Pfizer, Sanofi pull out checkbooks for separate year-end autoimmune pacts

Pfizer adds heft to obesity pipeline in $2B Yaopharma deal

Pfizer continues renewed obesity push with $150M upfront for Fosun unit's GLP-1 drug

Pfizer dips into China for another try at an obesity pill

OTR Therapeutics gets $100M from Pfizer Ventures, others to build asset portfolio

Pfizer Ventures gets behind Chinese biotech's $100M series A to boost R&D hub's capability

Bio/Pharmaceutical Outsourcing Report, October 2025 - Pfizer and Roche Place $10 Billion Bets on Obesity and Liver Disease Therapies as Trump Tightens Grip on Drug Pricing and Manufacturing - Yahoo Finance

Daiichi Sankyo avoids payout in long-running patent dispute with Pfizer’s Seagen

Pfizer-backed Triana scores $120M series B to take molecular glue degrader into clinic

Pfizer-allied molecular glue startup Triana collects $120M Series B

Pfizer culls ulcerative colitis candidate; Tiziana to try spinning out IL-6 drug